На главную
Результаты поиска “U.S. Pharmaceutical Sales Statistics” за 2015
Find market trends, forecasts and statistics for the restaurant industry in Passport
 
07:17
If you're researching the restaurant industry for any major market around the world, Passport it an excellent choice. This video demonstrates how to find market research reports, company profiles, expert analysis, industry trends, forecasts, and statistics in Passport.
Просмотров: 616 Chad Boeninger
Probability-based forecasting for U.S. generic drug sales.
 
03:28
Value of Insight VoiConsulting.com.
Просмотров: 358 Value Of Insight
The Truth About Cancer: A Global Quest - Episode 1
 
01:58:50
!! Free "A Global Quest" Episode 1!! "The True History of Chemotherapy & The Pharmaceutical Monopoly" If you would like to support our mission and own all Episodes of this eye-opening Docu-Series, please follow this link: http://bit.ly/agq-silver-ttac-yt --------------------------------------------------- Welcome to Episode 1 of "The Truth About Cancer: A Global Quest". This Episode is about the true history of Chemotherapy and the pharmaceutical monopoly. We welcome you to watch this Episode completely free. To watch Episode 2 of "A Global Quest" docu-series for FREE, click here: https://youtu.be/VK_sX5ko8SE Join TTAC's 900K+ FB fans: http://bit.ly/TTAC-Facebook-YT Follow us on PINTEREST: http://bit.ly/TTAC-Pinterest-YT Find us on INSTAGRAM: http://bit.ly/TTAC-Instagram-YT Visit our website: www.thetruthaboutcancer.com Our mission is to educate the world, expose lies & empower people with life-saving knowledge. Help us and share the truth, by clicking the SHARE button above! -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. ---------------------------------------------------------------------- Inside The Truth About Cancer Docu-Series --------------------------------------------------------------------- Doctors, researchers, experts, and survivors show you exactly how to prevent and treat cancer in our 3 original docu-series: "The Quest For The Cures”, “The Quest For The Cures Continues”, “The Truth About Cancer: A Global Quest”, and on our website: http://www.thetruthaboutcancer.com In our docu-series you’ll travel with Ty Bollinger who lost both his mother and father to cancer (as well as 5 other family members). Ty travels the country and the globe and sits down with the foremost doctors, researchers, experts, and cancer conquerers to find out their proven methods for preventing and treating cancer. Please join our email list to be notified of all upcoming events (including free airings of our docu-series): http://bit.ly/join-ttac-mission-yt Learn more about our latest docu-series “The Truth About Cancer: A Global Quest” here: http://bit.ly/agq-silver-ttac-yt --------------------------------------- About Ty Bollinger --------------------------------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book "Cancer - Step Outside the Box," which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docu-series’:”The Quest for The Cures”, “The Quest For The Cures Continues”, and “The Truth About Cancer: A Global Quest.” Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and is a regular guest on multiple radio and TV shows and writes for numerous magazines and websites. ---------------------------------------------------------------------------------------------------------------- thetruthaboutcancer, chemo truths, the truth about cancer, ty bollinger, truth about cancer, a global quest, truth about cancer global quest episode 1, truth about cancer episode 1, a global quest episode 1, does chemotherapy work, alternative cancer cures, how to beat cancer with natural cures, cancer truths, chemotherapy side effects, which natural cancer treatments work, best natural cancer treatment, what is the best treatment for breast cancer, best food to cure cancer
Просмотров: 3439841 The Truth About Cancer
Pfizer, Allergan Create Largest Pharmaceutical Merger
 
01:44
Pfizer and Allergan are set to reach a $150 billion deal that would create the world's largest drug maker in terms of sales, according to the Wall Street Journal.
Просмотров: 260 CBN - The Christian Broadcasting Network
Pharmaceutical Company Cuts Outlook Due to Patent Expirations and Strong Dollar
 
00:48
Pfizer's (PFE) new drugs pipeline gave their first quarter earnings a boost on Tuesday. The company beat estimates posting profits of $2.4B or $0.51 per share. Revenue was down on last year's numbers, coming in at $10.86 billion. The pharmaceuticals giant was hurt by the strong dollar and a wave of patent expirations. Pfizer cut its full year outlook for 2015 and lowered revenue forecasts to to $46.5 billion. The company saw a 44% increase in global vaccine revenue and agreed to buy injectable drugs maker Hospira for $16 billion back in February. Pfizer stock is up around 11 percent this year. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 85 TheStreet: Investing Strategies
Apotex International - An Overview
 
06:18
Apotex believes that every man, woman and child is entitled to affordable medical care and freedom from pain and suffering. For close to 40 years, Apotex has met the healthcare challenges of tomorrow and fought hard to build a successful worldwide pharmaceutical company. Through a strategy of vertical integration, Apotex has built an exceptional scientific and manufacturing base that supports a global sales and marketing infrastructure. We have done this on the heels of our continued commitment to excellence. Apotex is focused on meeting the world’s need for the highest quality, affordable medicines. We have built the facilities, the scientific R&D base, and the technology to meet the healthcare needs of the world for today and tomorrow. With an established network of international affiliates and distributors, our medicines are present in more than 115 countries.
Просмотров: 3420 Apotex Inc.
Global Cervical Cancer Drug Industry 2015 Market Research Report
 
00:31
Big Market Research “Global Cervical Cancer Drug Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast. The Global Cervical Cancer Drug Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Cervical Cancer Drug industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cervical Cancer Drug market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Read more details at: http://www.bigmarketresearch.com/global-cervical-cancer-drug-industry-2015-deep-research-report-market The Global Cervical Cancer Drug Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Cervical Cancer Drug industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 164 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Table of Contents 1 Industry Overview 1.1 Definition and Specifications of Cervical Cancer Drug 1.2 Classification of Cervical Cancer Drug 1.3 Applications of Cervical Cancer Drug 1.4 Industry Chain Structure of Cervical Cancer Drug 1.5 Industry Regional Overview of Cervical Cancer Drug 2 Manufacturing Cost Structure Analysis of Cervical Cancer Drug 2.1 Raw Material Suppliers and Price Analysis of Cervical Cancer Drug 2.2 Equipment Suppliers and Price Analysis of Cervical Cancer Drug 2.3 Labor Cost Analysis of Cervical Cancer Drug 2.4 Other Costs Analysis of Cervical Cancer Drug 3 Technical Data and Manufacturing Plants Analysis 3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014 3.2 Manufacturing Plants Distribution of Global Key Cervical Cancer Drug Manufacturers in 2014 3.3 R&D Status and Technology Source of Global Cervical Cancer Drug Key Manufacturers in 2014 3.4 Raw Materials Sources Analysis of Global Cervical Cancer Drug Key Manufacturers in 2014 4 Production Analysis of Cervical Cancer Drug by Regions, Technology, and Applications 4.1 Global Production of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 4.2 Global Production of Cervical Cancer Drug by Technology 2010-2015 4.3 Global Production of Cervical Cancer Drug by Applications 2010-2015 4.4 Price Analysis of Global Cervical Cancer Drug Key Manufacturers in 2015 5 Sales and Revenue Analysis of Cervical Cancer Drug by Regions 5.1 Global Sales of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 5.2 Global Revenue of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 5.3 Global Price Analysis of Cervical Cancer Drug Sales by Regions (US, EU, China, Japan, etc.) 2010-2015 5.4 Global Price, Cost and Gross of Cervical Cancer Drug 2010-2015 6 Analysis of Cervical Cancer Drug Production, Supply, Sales and Market Status 2010-2015 6.1 Capacity and Production of Cervical Cancer Drug 2010-2015 6.2 Production Market Share Analysis of Cervical Cancer Drug 2010-2015 6.3 Sales Overview of Cervical Cancer Drug 2010-2015 6.4 Supply, Sales and Shortage of Cervical Cancer Drug 2010-2015 Enquire about report: http://www.bigmarketresearch.com/report-enquiry/300004
Просмотров: 43 Moira Warren
CAREERS IN PHARMA – D.Pharma,B.Pharma,M.Pharma,Pharmacists,Research,Institutions,Salary Package
 
06:19
CAREERS IN PHARMA.Go through the career opportunities of PHARMA, Govt jobs and Employment News channel from Freshersworld.com – The No.1 job portal for freshers in India. Visit http://www.freshersworld.com?src=Youtube for detailed Career information,Institutions,Higher Education details of PHARMA. With the heightening number of diseases and health problems, there requires a responsible person who supplies medicines. Supplying medicines cannot be done by any individual, where one requires to have completed pharmacy course for the same. The safe and effective utilization of Pharmaceutical drugs is well accomplished with Pharma graduates. Apart from distributing medications and compounding, Pharma field bears in mind clinical services, health care, revising medications and also providing drug information. For patients to gain optimistic health outcomes, Pharmacists are considered as Pharmaceutical experts who are well proficient in drug therapy. The Pharma course is highly in demand and has excellent job opportunities and hence abundant students prefer the course. There are surplus courses when Pharma is considered. Here are a few courses that fall under Pharma field in India. • B.Pharm Bachelor of Pharmacy • B.Pharm (Hons) Bachelor of Honours • B.Pharm + MBA Bachelor of Pharmacy with Master of business administration • B.Pharm (Pharmaceutical chemistry) Bachelor of Pharmacy in Pharmaceutical chemistry • B.Pharm (Pharmaceutics) Bachelor of Pharmacy in Pharmaceutics • B.Pharm (Pharmacognosy) Bachelor of Pharmacy in Pharmacognosy • B.Pharm (Unani) Bachelor of Pharmacy in Unani • B.Pharma (Pharmacology) Bachelor of Pharmacy in Pharmacology • Bachelor of Ayurvedic Pharmacy • MBA (Pharma. Technology) • M.Pharm (DDRS) • M.Pharm • M.Pharm ( Biotechnology) • M.Pharm (Clinical Pharmacy) • M.Pharm (Clinical practice & research) • M.Sc. (Pharmacy) • Ph.D. (Pharmacy) • Pharm.D When a deep look is taken onto career options for B.Pharma graduates, there are a number of paths for them to build and enhance their career. A few roles where they can play as pharmacists are drug therapist, pathology lab, drug inspector, research officer, bio-technology industries, chemical or drug technician, hospital drug coordinator, pharmacists, health inspector, research and development, scientists, making prescriptions to patients and more. B.Pharma graduates are the ones who get attractive pay where average salary for males is 119,137 to 276,000. In the same manner average female pharmacists gain about 99,000 to 228,000 in India. Here is a list of few top companies which recruit pharmacists and provide a good package. • Ranbaxy • Cipla • Ipca laboratories • Dr.Reddy’s laboratories • Cadila health care • Aurobindo Pharma • Aventis Pharma • Sun Pharma industries • Lupin labs • Glaxo Smith Kline Pharma (GSK) and many more. • To gain entry into government jobs, B.Pharma graduates are required to clear UPSC exam in order to get recruited for central and state government jobs like. Drug inspector, assistant chemical examiner and drug analyst are certain roles required in state and central government. All government and central government institutions, hospitals and health care centers recruit pharmacists with written entrance exams for certain specific roles. So researching and getting updated with the latest news is a good option for pharmacist graduates. For more jobs & career information and daily job alerts, subscribe to our channel and support us. You can also install our Mobile app for govt jobs for getting regular notifications on your mobile. Freshersworld.com is the No.1 job portal for freshers jobs in India. Check Out website for more Jobs & Careers. http://www.freshersworld.com?src=Youtube - - ***Disclaimer: This is just a career guidance video for fresher candidates. The name, logo and properties mentioned in the video are proprietary property of the respective companies. The career and job information mentioned are an indicative generalised information. In no way Freshersworld.com, indulges into direct or indirect recruitment process of the respective companies.
Просмотров: 236515 Freshersworld.com Jobs & Careers
Inside the $160B Pfizer-Allergan Record Deal
 
02:56
Nov. 23 -- Pfizer Inc. and Allergan Plc said they would combine operations in a stock transaction worth about $160 billion, creating a drugmaking behemoth with products from Viagra to Botox and a low-cost tax base. Jefferies Chief Market Strategist David Zervos and Bloomberg's Cynthia Koons speak on "Bloomberg ‹GO›."
Просмотров: 4718 Bloomberg
Lupin Q4 Net Profit Slips; Slow Growth Dents Margins: Interview with CEO, Nilesh Gupta
 
13:39
Drug firm Lupin saw consolidated net profit fell 1.1 percent to Rs 547 crore in January-March quarter from Rs 553 crore in the corresponding quarter last fiscal. During the period, its revenue was alm
Просмотров: 396 CNBC-TV18
POLICE DEPT. EXPOSE BIG PHARMA SALARIES BUT, WHAT IF IT WAS US?
 
06:51
From an article on Activist Post- fair use: This is great. Great in the sense someone is actually DOING something to combat this constant and ever growing TYRANNY. This police dept. exposed the names, e-mail addresses, and phone numbers of some of America's biggest drug dealers. Great job! I agree absolutely and 100%. So, what's my problem? I thought this goverment was going after whistleblowers? Like Snowden and what's his...err...HER name? I cannot help but, wonder, if WE did this, would we just make the pages of Activist Post or would we be asking Snowden to scoot over?
Просмотров: 18 Medical Menudo420
RANBAXY LABORATORIES LTD - Recruitment Notification 2017– Jobs,Openings,Exam dates & results
 
03:41
Latest RANBAXY LABORATORIES LTD Recruitment Notification 2017. Apply today for Jobs & Careers at RANBAXY LABORATORIES LTD – Trainee jobs,The Govt jobs and Employment News channel from Freshersworld.com – The No.1 job portal for freshers in India. Visit http://www.freshersworld.com/ranbaxy-laboratories-jobs-careers/4444191?src=Youtube for detailed job information, recruitment notification, eligibility criteria, application form, general dates, exam results of RANBAXY LABORATORIES LTD. Ranbaxy Laboratories Ltd is a multinational pharmaceutical company that is based in India. The company spends its maximum resources on research and development department. Thus, the number of candidates being selected in R&D is higher than other departments. When it comes to research, the candidates with master degree and doctoral in various fields of medical sciences are usually preferred. Doctors with MD degree are chosen for researcher field. Candidates with doctoral in biotechnology, pharmaceutical or other allied fields are chosen as research assistant. Candidates with master degree in chemistry, biotechnology and other departments are chosen for research associate positions. The Ranbaxy Laboratories limited recruitment happens through campus drive and also through direct recruitment process. The candidates can apply for the positions through the official site. Not just science candidates, the candidates from varying fields like engineering to management are chosen for various departments starting from sales to general administration. When it comes to selection process of Ranbaxy jobs, the candidates have to take up a technical written test, group discussion and personal interview. The written test’s scope, pattern and syllabus would vary based on the educational requirement and type of job profile. The group discussion round would involve a general topic where the communication skills and interpersonal skills of the candidates would be tested. The written test for pharma jobs would not be the same as that of the test for management executives. The group discussion and the other levels would be common for almost all the positions. But, the importance given to each level would vary. When it comes to research and development department, the group discussion would not be of higher value when compared to the sales team recruitment process. .Visit Preparation and placement tips for RANBAXY LABORATORIES LTD jobs at : http://placement.freshersworld.com?src=Youtube For more jobs & career information and daily job alerts, subscribe to our channel and support us. You can also install our Mobile app for govt jobs for getting regular notifications on your mobile. Freshersworld.com is the No.1 job portal for freshers jobs in India. Check Out website for more Jobs & Careers. http://www.freshersworld.com?src=Youtube - - ***Disclaimer: This is just a career guidance video for fresher candidates. The name, logo and properties mentioned in the video are proprietary property of the respective companies. The career and job information mentioned are an indicative generalised information. In no way Freshersworld.com, indulges into direct or indirect recruitment process of the respective companies.
Просмотров: 27865 Freshersworld.com Jobs & Careers
Biopharmaceutical Company Beats on Earnings on Growing Sales of Depression Drug
 
00:50
Drug maker Bristol Myers (BMY) posted earnings of $0.71 per share on Tuesday, beating analyst estimates. Revenue was also higher than expected, coming in at $4.04B - a 6 percent increase on last year's numbers.The bio-pharmaceutical company benefited from increased sales of its depression treatment Abilify this quarter, but is facing competition from similar copies of the drug in the US. The New York based company was hit by the strong dollar but remains optimistic about its pipeline of immunotherapy cancer drugs and latest Hepatitis C treatments. Sales of the company's latest cancer drug Opdivo missed Wall Street expectations which knocked the stock price in this morning. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 84 TheStreet: Investing Strategies
TPP’s Biggest Winner: Big Pharma - The Ring Of Fire
 
10:46
Now that Fast Track has passed the hurdles of Congress, President Obama is absolutely giddy with excitement that his TPP trade deal might finally be happening. The best economists tell us that we’ll lose more jobs from this deal than we did from NAFTA and CAFTA, but that hasn’t stopped the President from telling us that this is the most progressive trade deal in history. The little information that has been leaked about the TPP tells us that the only groups to benefit will be corporations, specifically the drug industry. America’s Lawyer, Mike Papantonio, and attorney Howard Nations talk about that. Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Follow more of our stories at http://www.RingofFireRadio.com Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 895 The Ring of Fire
FDA Gives Pfizer Nod for Breast Cancer Drug Two Months Early
 
02:55
Disney, Macy's and Green Mountain Coffee Roasters are in focus in earnings news and Pfizer gets the greenlight from the FDA for a breast cancer drug two months early. Disney posted better than expected earnings and higher revenue in its latest quarter thanks to strong topline numbers from its TV networks and sales of paraphernalia associated with the animated movie Frozen. Macy's is a stock to watch today as it raised its outlook for the year and plans to buy BlueMercury for $210 million in cash. The FDA has granted early approval of Pfizer's drug used to treat advanced stage breast cancer. The approval of Inbrance came two months early. Pfizer needs some big-selling new drugs to boost its earnings, following patent expirations on many of its biggest brands and a relatively thin supply of promising drugs in late-stage trials. Pfizer said the drug is available to order immediately through specialty pharmacies. Keurig Green Mountain Coffee Roasters turns in first quarter earnings results today. KeyBank Capital Markets reiterates its BUY rating on GMCR with a $175 price target. Sales of single K Cups versus sales of brewers are expected to drive numbers. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 159 TheStreet: Investing Strategies
Statistical Analysis and Interpretation Why it is important for a Master's Student
 
00:46
http://www.statswork.com/ . Statswork has been established with an outlook to provide high quality statistical and biostatistical services to a wide range of industry sectors that includes: Corporate Academic FMCG Logistics R & D Pharmaceutical and Banking Based on our vast experience spanning over 15 years, we have been able to deliver services that are accurate, concise and extremely intrinsic to overall business and academic objectives. Our highly qualified personnel, trained from reputed international universities like Harvard are well experienced in supporting clients with the requisite skills and know-how to execute complex statistical / biostatistical analysis and research activities. Our repertoire for servicing fortune 500 companies has propelled us to the forefront, thereby emerging as a trusted name in the field of statistical and biostatistical analytics.
Просмотров: 455 Stats Work
'Big pharma profiteering must be stopped' – Doctors Without Borders chief
 
02:18
The 2014 Ebola epidemic highlighted the global threat of disease. And while the need for new drugs and vaccines is clear, the research is often driven by profit. How can these opposites be reconciled, and what challenges do aid organisations face in the field? Oksana is joined by Dr Joanne Liu, the International President of Doctors Without Borders, for a dose of these issues. WATCH FULL INTERVIEW HERE: https://youtu.be/_zyEKRzrO_0 RT LIVE http://rt.com/on-air Subscribe to RT! http://www.youtube.com/subscription_center?add_user=RussiaToday Like us on Facebook http://www.facebook.com/RTnews Follow us on Twitter http://twitter.com/RT_com Follow us on Instagram http://instagram.com/rt Follow us on Google+ http://plus.google.com/+RT Listen to us on Soundcloud: https://soundcloud.com/rttv RT (Russia Today) is a global news network broadcasting from Moscow and Washington studios. RT is the first news channel to break the 1 billion YouTube views benchmark.
Просмотров: 8245 RT
Johnson & Johnson Pharma Division Provides Earnings Bright Spot
 
00:51
Johnson and Johnson (JNJ) posted earnings on Tuesday that topped Wall Street estimates. The health and personal care giant faced currency headwinds due to the strong dollar but has increased its outlook for 2015, boosting guidance to $6.10-$6.20 per share for the year, up from $6.04-$6.19 per share. The company reported profits of $1.71 per share, up from last year's numbers and beating Wall Street estimates. Revenue was down almost 9 percent from $19.5 billion to $17.8 billion but topped estimates. The brand has topped estimates for the last 17 quarters in a run of over four years. The company's pharmaceutical division was a bright spot. Sales of its arthritis drug Simponi jumped 30 percent in the U.S. market. Johnson and Johnson also announced last month that it had received FDA approval for a new schizophrenia treatment which only needs to be administered four times a year, giving patients greater independence from their dosing. Johnson and Johnson shares have dropped almost 4 percent in the last year. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 138 TheStreet: Investing Strategies
How much does it cost to develop a new drug?
 
02:27
Pharmaceutical companies and civil society confront their calculations for the cost of a new drug. Footage: Anne Vigna Edition: Miguel Angel Gavilanes Medicamentalia 2015
Просмотров: 219 Fundación Civio
Let’s Be Honest: If Any Republican Wins In 2016, We’re Screwed - The Ring Of Fire
 
03:18
For the last week, I’ve been thinking about what I saw in the Republican debates. I’ve read analyses from every possible source, and I think what bothers me the most is that no one is saying the painfully obvious: If any one of those people that we saw on the stage last Wednesday night wins the presidency, then we, as a country, are completely screwed. I’m incredibly concerned about the fact that not one single Republican that took the stage that night was able to offer a single, cohesive, coherent policy plan. ON ANY ISSUE. The only thing that came close were their insane ideas to build a wall along the Southern border and to bomb the Middle East into oblivion. But those are the same backwards ideas that the Republican Party has been offering up for 35 years. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 5245 The Ring of Fire
Los Angeles Declares Homelessness An Emergency
 
00:52
Los Angeles officials on Tuesday moved to declare the rising problem of homelessness an "emergency" in the city and proposed spending $100 million to provide permanent housing and shelters to help the city's 26,000 indigent. Mayor Eric Garcetti joined several City Council members in unveiling the plan, which follows an increase in the city's homeless population from just under 23,000 two years ago, according to the Los Angeles Homeless Services Authority. He said of the homelessness problem, "It has cost us money, and most importantly it's cost us lives." http://feeds.reuters.com/~r/Reuters/domesticNews/~3/M5p6kJUqTXo/story01.htm http://www.wochit.com This video was produced by Wochit using http://wochit.com
Просмотров: 231 Wochit News
Global Disposable Medical Gloves Industry 2015 Deep Market Research Report
 
00:31
Big Market Research “Global Disposable Medical Gloves Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2020. The Global Disposable Medical Gloves Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Disposable Medical Gloves industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Disposable Medical Gloves market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Read more details at: http://www.bigmarketresearch.com/global-disposable-medical-gloves-industry-2015-deep-research-report-market The Global Disposable Medical Gloves Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Disposable Medical Gloves industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 165 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Table of Contents 1 Industry Overview 1.1 Definition and Specifications of Disposable Medical Gloves 1.2 Classification of Disposable Medical Gloves 1.3 Applications of Disposable Medical Gloves 1.4 Industry Chain Structure of Disposable Medical Gloves 2 Manufacturing Cost Structure Analysis of Disposable Medical Gloves 2.1 Raw Material Suppliers and Price Analysis of Disposable Medical Gloves 2.2 Equipment Suppliers and Price Analysis of Disposable Medical Gloves 2.3 Labor Cost Analysis of Disposable Medical Gloves 2.4 Other Costs Analysis of Disposable Medical Gloves 3 Technical Data and Manufacturing Plants Analysis 3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014 3.2 Manufacturing Plants Distribution of Global Key Disposable Medical Gloves Manufacturers in 2014 3.3 R&D Status and Technology Source of Global Disposable Medical Gloves Key Manufacturers in 2014 3.4 Raw Materials Sources Analysis of Global Disposable Medical Gloves Key Manufacturers in 2014 4 Production Analysis of Disposable Medical Gloves by Regions, Technology, and Applications 4.1 Global Production of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 4.2 Global Production of Disposable Medical Gloves by Technology 2010-2015 4.3 Global Production of "& B1 &" by Applications 2010-2015 4.4 Price Analysis of Global Disposable Medical Gloves Key Manufacturers in 2015 5 Sales and Revenue Analysis of Disposable Medical Gloves by Regions 5.1 Global Sales of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 5.2 Global Revenue of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 5.3 Global Price Analysis of Disposable Medical Gloves Sales by Regions (US, EU, China, Japan, etc.) 2010-2015 5.4 Global Price, Cost and Gross of Disposable Medical Gloves 2010-2015 6 Analysis of Disposable Medical Gloves Production, Supply, Sales and Market Status 2010-2015 6.1 Capacity and Production of Disposable Medical Gloves 2010-2015 6.2 Production Market Share Analysis of Disposable Medical Gloves 2010-2015 6.3 Sales Overview of Disposable Medical Gloves 2010-2015 6.4 Supply, Sales and Shortage of Disposable Medical Gloves 2010-2015 Enquire About Report: http://www.bigmarketresearch.com/report-enquiry/300690
Просмотров: 150 Melvin Wells
This Is How I Talk - SNL
 
04:51
After getting caught imitating his boss (Leslie Jones), a new employee (Louis C.K.) must play off the impression as his real talking voice in order to not get fired. Subscribe to SNL: https://goo.gl/tUsXwM Get more SNL: http://www.nbc.com/saturday-night-live Full Episodes: http://www.nbc.com/saturday-night-liv... Like SNL: https://www.facebook.com/snl Follow SNL: https://twitter.com/nbcsnl SNL Tumblr: http://nbcsnl.tumblr.com/ SNL Instagram: http://instagram.com/nbcsnl SNL Pinterest: http://www.pinterest.com/nbcsnl/
Просмотров: 10748833 Saturday Night Live
Pope Knows Best: Climate Action Is Imperative and a Responsibility - The Ring Of Fire
 
08:09
Pope Francis’ visit to the United States came with a clear message for U.S. Congress, and it preached resistance to their warmonger mentality, hatred, bigotry, and unwillingness to help those in need. He also briefly talked about climate change, and how action on it could make a huge difference. The Pope made it clear that the ideas he promotes aren’t liberal agendas, but human and moral responsibilities. Ring of Fire’s Sam Seder and Farron Cousins discuss why such climate inaction is prevalent in the United States. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 1184 The Ring of Fire
Healthcare: Top 3 Drug Approvals of 2015 *** INDUSTRY FOCUS ***
 
21:18
This episode we're highlighting what we think are the most significant, needle-moving drugs to hit the market this year. This podcast was recorded on 12/2/2015. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Просмотров: 144 The Motley Fool
How Big Oil Conquered the World
 
01:11:27
TRANSCRIPT AND SOURCES: https://www.corbettreport.com/?p=16888 From farm to pharmaceutical, diesel truck to dinner plate, pipeline to plastic product, it is impossible to think of an area of our modern-day lives that is not affected by the oil industry. The story of oil is the story of the modern world. And this is the story of those who helped shape that world, and how the oil-igarchy they created is on the verge of monopolizing life itself.
Просмотров: 1014285 corbettreport
Global Urinary Incontinence Products Market 2015-2019 Size, Trends, Industry
 
00:31
Global Urinary Incontinence Products Market 2015-2019 Trends, Demand, Landscape, Growth, Research, Production, Applications, Opportunities, Segmentation and Forecast Complete Report At: http://www.researchbeam.com/global-urinary-incontinence-products-2015-2019-market Report Overview: About Urinary Incontinence Products Urinary incontinence is any involuntary urine leakage; it may occur as a result of a number of deformities, such as abnormal function of the lower urinary tract, overactive bladder, and the result of other illnesses. It is estimated that about 50 percent of women suffer from urinary incontinence at some time in their lives. The prevalence of this in young women is usually less. The prevalence of stress and mixed incontinence is expected to be higher than urge incontinence. The prevalence of urinary incontinence in adult men is 5 percent, and most cases are related to prostate diseases. The severity depends on the psychological, physical, and social well-being of the affected individuals. Analysts forecast the Global Urinary Incontinence Products market to grow at a CAGR of 8.12 percent over the period 2014-2019. Covered in this Report This report covers the present scenario and the growth prospects of the Global Urinary Incontinence Products market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of different types of urinary incontinence treatment products. Report, the Global Urinary Incontinence Products market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Global Urinary Incontinence Products market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key Regions • Americas • APAC • EMEA Key Countries • Germany • Japan • US Key Vendors • American Medical Systems • B. Braun Melsungen • C.R. Bard • Coloplast • Covidien • Kimberly-Clark • Svenska Cellulosa Aktiebolaget • Unicharm Other Prominent Vendor • Apexmed International • Asid Bonz • BioDerm • Boston Scientific • Caldera Medical • CompactCath • ConvaTec • Cook Medical • Cure Medical • Daio Paper • Dileh Medical Supplies • DSG International • Dynarex • Ethicon (Johnson and Johnson) • First Quality Enterprises • Fu Burg Industrial Market Driver • Growing Aging Population • For a full, detailed list, view our report
Просмотров: 294 Lokesh Gautam
Wedding attracts foreign visitors in large numbers
 
03:03
(26 Apr 2011) SHOTLIST 1. Tower of London with tour boat sailing past on river in foreground 2. Tower of London walls and buildings 3. Tourists clambering down stairs on Tower of London rampart 4. Reverse shot of group of American tourists, all dressed identically in red outfits and hats with American flags, looking at Tower of London 5. Front view of Americans standing in line 6. Tourists displaying hands all with identical rings, copies of Kate Middleton's engagement ring 7. SOUNDBITE: (English) Marcia Anderson, 49-year-old pharmaceutical sales representative from Oklahoma City, United States: "London's just a great city. Great history - obviously the Tower and everything here. But then to have the royals and to be able to come and see all the royal things...." SOUNDBITE: (English) Mary Boepple, 49-year-old retiree from Cyprus, Texas, United States - and twin sister of Marcia Anderson: "The thousands of years of history is what's exciting and walking in their (the royal family's) footsteps and enjoy the places that we know that they've been." 8. Tourists walking along Tower of London concourse 9. Tourist taking photograph 10. Tourists walking along walls of Tower of London 11. SOUNDBITE: (English) John Keohane, Chief Yeoman Warder of the Tower of London: "There's so much tradition and this is what I think - especially our visitors from the United States or (elsewhere) abroad - come here to see. They want to come and see all what the British monarchy is all about and why it's so important to all of us that live here in this great country." 12. Group of German tourists looking at guide book 13. Tourists' hands and guide book 14. SOUNDBITE: (German) Jonathan Soenenan, 30 year-old tourist from Berlin, Germany: "We hadn't planned to come here for the royal wedding and it's a coincidence that it's happening while we're here. There's lots going on that we didn't expect, but I might go down on the day and wave at the royal couple!" 15. Tourists walking along concourse 16. SOUNDBITE: (Italian) Massimo Caneva, tourist from Treviso, Italy: "It's fun for the children, especially to see the crown jewels, as well as other things connected to queens and kings, and so they're having a great time." 17. Caneva and family walking away from camera 18. Long shot of Tower of London concourse with tourists walking 19. Tourist taking photograph next to river with Tower of London in background - pans right to show group posing for photograph in front of Tower Bridge 20. Tourists with camera looking at river 21. SOUNDBITE: (English) Jacqueline French, spokesperson for London and Partners, the official promotional agency for London: "What we are hoping is that the royal wedding will really put a spotlight on London. There's an approximate four (b) billion people will be watching the wedding overseas. We've got the queen's jubilee next year, as well as the 2012 Olympic and Paralympic Games. And all of this will create a sense of fun and great atmosphere in London that hopefully people will want to be a part of." 22. Group of tourists by river with map and camera 23. Wide shot of Tower Bridge and River Thames with tourists walking STORYLINE: The British capital is witnessing a boom in tourism ahead of Friday's royal wedding. Some London landmarks are reporting swelling numbers of international visitors, many of whom say they're here primarily because of Prince William and Kate Middleton's 29 April nuptials. Tourists were flocking to the Tower of London on Tuesday. The iconic landmark by the River Thames, with its 900 years of royal history, is a regular stop on the tourist trail. But numbers are definitely up, according to officials. They wore matching red hats, complete with American flags, and identical red outfits. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/140aeab52eef79898706b0d8f244b330 Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 38 AP Archive
Hold IPCA Laboratories, says Mayuresh Joshi
 
02:47
Mayuresh Joshi says that If one looks at the import ban and the statistics involved with the US sales for Ipca Laboratories, FY14 as a perspective, they contributed around Rs 414 odd crore which is 12 percent of the total sales, 20 percent of their exports and if I distinguish between domestic and EPI – its around 61:39 ration. Having said that, couple of their molecules from the Ratlam facility has not been affected by the ban and they probably account around 45 percent of the US sales. Investors should hold on to the stock. We are very optimistic on the stock from FY17 perspective.
Просмотров: 445 Angel Broking
Antidepressant Market in the US 2015 2019
 
00:56
Antidepressant Market in the US 2015 2019 http://www.marketresearchstore.com/report/antidepressant-market-in-the-us-2015-2019-4322 According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Table of Content 1. Executive Summary 2. List of Abbreviations 3. Scope of the Report 3.1 Market Overview 3.2 Product Offerings 4. Product Profiles 4.1.1 Celexa 4.1.2 Fetzima 4.1.3 Lexapro 4.1.4 Viibryd 4.1.5 Cymbalta 4.1.6 Prozac 4.1.7 Symbyax 4.1.8 Paxil 4.1.9 Wellbutrin 4.1.1 Abilify 4.1.11 Effexor 4.1.12 Pristiq 4.1.13 Zoloft 5. Market Research Methodology 5.1 Market Research Process 5.2 Research Methodology 6. Introduction 7. Disorder Overview 7.1 Depression & its Types 7.1.1 Major Depressive Disorder 7.1.2 Persistent Depressive Disorder 7.1.3 Psychotic Depression 7.1.4 Post-partum Depression 7.1.5 Seasonal Affective Disorder 7.1.6 Bipolar Disorder 7.2 Etiology 7.3 Epidemiology 7.3.1 Bipolar Disorder Among Adults 7.3.2 Dysthymic Disorder Among Adults 7.3.3 Major Depression Among Adults 7.3.4 Major Depression Among Adolescents 7.4 Treatment & Management 7.5 Economic Burden 8. Market Landscape 8.1 Market Overview 8.2 Market Size and Forecast 8.3 Five Forces Analysis 9. Market Segmentation by Mechanism of Action 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 17.1 Competitive Scenario 17.1.1 Key News 17.1.2 Mergers and Acquisitions 17.2 Market Share Analysis 2014 17.2.1 Competitive Assessment of the Top Drugs for Depression 17.2.2 Eli Lilly 17.2.3 Otsuka Pharmaceutical 17.2.4 Pfizer 17.2.5 GlaxoSmithKline 17.2.6 Actavis 17.3 Other Prominent Vendors 18. Key Vendor Analysis 18.1 Actavis 18.1.1 Key Facts 18.1.2 Business Description 18.1.3 Business Segmentation 18.1.4 Business Segmentation by Revenue 2012 and 2013 18.1.5 Sales by Geography 18.1.6 Business Strategy 18.1.7 Key Information 18.1.8 SWOT Analysis 18.2 Eli Lilly 18.2.1 Key Facts 18.2.2 Business Overview 18.2.3 Business Segmentation by Revenue 18.2.4 Sales by Geography 18.2.5 Business Strategy 18.2.6 Key Information 18.2.7 SWOT Analysis 18.3 GlaxoSmithKline 18.3.1 Key Facts 18.3.2 Business Overview 18.3.3 Business Segmentation 18.3.4 Business Segmentation by Revenue 2012 and 2013 18.3.5 Sales by Geography 18.3.6 Pipeline Products 18.3.7 Business Strategy 18.3.8 Key Information 18.3.9 SWOT Analysis 18.4 Otsuka Pharmaceutical 18.4.1 Key Facts 18.4.2 Business Overview 18.4.3 Business Segmentation by Revenue 2014 18.4.4 Business Segmentation by Revenue 2013 and 2014 18.4.5 Geographical Segmentation by Revenue 2014 18.4.6 Business Strategy 18.4.7 Recent Developments 18.4.8 SWOT Analysis 18.5 Pfizer 18.5.1 Key Facts 18.5.2 Business Overview 18.5.3 Business Segmentation by Revenue 2013 18.5.4 Business Segmentation by Revenue 2012 and 2013 18.5.5 Geographical Segmentation by Revenue 18.5.6 Business Strategy 18.5.7 Key Developments 18.5.8 SWOT Analysis
Просмотров: 146 Market Research Store
As first female libido drug hits the market, more options in
 
00:33
YOUR DESCRIPTION HAS REACHED THE LIMIT OF CHARACTERS ALLOWED AND WAS CUT. WASHINGTON (CBS NEWS) -- Most women with low sexual desire won't rush to get the first prescription drug to boost female libido when it becomes available on Saturday. But they may have more options down the road. Addyi is a daily medication that can't be taken with alcohol or certain other drugs, which will likely limit its use. But experts believe those restrictions could spur development of better treatments for women's sexual problems after more than a decade of neglect by most of the world's large drugmakers. Kim Wallen, a psychology professor at Emory University, says Addyi represents a historic milestone that may open the door to more drugs targeting desire in men and women. Where Viagra and other men's erectile dysfunction drugs work by increasing blood flow to the genitals, Addyi acts on brain chemicals associated with desire. "This is the first time that a drug, for either men or women, has been approved strictly to increase sexual desire," Wallen says. "That legitimizes many other drugs that are in development." Treatments for women's libido issues are an untapped financial opportunity for drugmakers. Analysts estimate the market could be worth over billion, based on academic estimates that between 5 million and 9 million U.S. women may suffer from desire disorders. But the area hasn't been a research priority for drugmakers in many years. Beginning in the 1990s, Pfizer, Bayer and Procter Gamble all studied - then discarded - drugs targeting female libido. Addyi itself was developed by the German conglomerate, Boehringer Ingelheim, then sold to Sprout Pharmaceuticals after the Food and Drug Administration rejected the medication due to lackluster effectiveness and issues like nausea, fatigue and dizziness. It took Sprout four years to win FDA approval for Addyi, which was finally granted in August, on the third try. "They really struggled with this, even agonized over the decision," said CBS News chief medical correspondent Dr. Jon LaPook. "Because they said the benefits were kind of modest and there were some significant side effects they were worried about: dizziness, sleepiness, and when used with alcohol, fainting." The drug, which acts on brain chemicals associated with mood and appetite, will come with a bold warning label about the risks of fainting if combined with alcohol or certain medications. Additionally, doctors and pharmacists must complete an online certification process to show they understand the drug's risks. Dr. Lisa Dabney says several patients have asked her about Addyi, but they generally lose interest after she explains they cannot drink alcohol while taking the daily medication. "It's definitely an option that's going to help patients," says Dabney, of New York's Mt. Sinai hospital. "But it's going to have a limited patient audience because of the alcohol restrictions and the fact that you have to take it every day." Still, some women credit the drug with saving their relationships. Amanda Parrish, 52, had been married for three years when she realized she was avoiding sex with her husband. Her doctor said it was natural to lose sexual interest with age and suggested she try a vibrator. But nothing worked until Parrish enrolled in a trial of Addyi, which was studied in women who report distress due to a lack of libido. "It just brought me back to where I was as far as being flirty and playful," says Parrish, who lives in Nashville. "I went back to the days of leaving notes on his window, in his car, on his mirror in the morning." Sheri Mike, a 34-year-old mother of two, told CBS News she hopes it will make a difference for her. "I've tried vitamins, me and my husband have tried counseling, I've tried hypnotherapy, but none of those have worked," she said."The lack of desire, the lack of sexual thoughts, no libido -- it's just this one area that's kind of holding us back from being truly happy." Experts generally describe Addyi's effect as "modest." In company studies, women taking the drug that's also called flibanserin reported a slight uptick in sexually satisfying events each month. Their answers to separate questionnaires indicated they experienced a slight increase in desire and a slight decrease in stress. Analysts from Evercore ISI estimate Addyi could generate sales of 00 million annually. That's far below the blockbuster numbers once discussed by experts and the billion that Valeant Pharmaceuticals recently agreed to purchase Sprout. But the buyout has revived interest in a handful of competitors developing alternate treatments. Those products include nasal sprays, injections and antidepressant pills. It could be years before any of them reach patients. That's because the field of women's sexual medicine remains a small one, comprised of tiny companies with limited resources. Leading the field is Cranbury, N.J.-based Palatin Technologies Inc. which is studying an injectable
Просмотров: 447 LOCAL 12
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
 
01:13
1. Investigation of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals Bowel Disorders Market is Buoyant and Poised for Growth NBB6-52 November 2012 2. ContentsSection Slide Numbers Executive Summary 14 Market Overview 20 • Definitions 21 • Overview of Inflammatory Bowel Disease 23 o Incidence and Prevalence of Inflammatory Bowel Disease 24 o Diagnosis of Inflammatory Bowel Disease 25 o Clinical Severity of Inflammatory Bowel Disease 27 o Assessment of Disease Activity in IBD Clinical Trials 29 o Anatomic Extent of Ulcerative Colitis 31 o Clinical Guidelines 33 • Overview of Irritable Bowel Syndrome 38 o Diagnosis of IBS 39 o Assessment of Disease Activity in IBS Clinical Trials 40 o Clinical Trial Design Guidance—IBS 41 o Clinical Guidelines—IBS 43 • Personalized Medicine in Bowel Disorders 44 • Key Questions This Study Will Answer 45 • Market Overview—Segmentation 46NBB6-52 3. Substance (continued)Section Slide Numbers External Challenges: Drivers and Restraints 57 Forecasts and Trends 69 Demand Analysis 84 Market Share and Competitive Analysis 87 Inflammatory Bowel Disease Prescription Pharmaceuticals Segment 123 •5-ASA Subsegment Breakdown 127 •Corticosteroid Subsegment Breakdown 138 •TNF Inhibitor Subsegment Breakdown 149 •Non-TNF Biologicals Subsegment Breakdown 160 •Novel Orals Subsegment Breakdown 169 Irritable Bowel Syndrome Prescription Pharmaceuticals Segment 177 The Last Word (Conclusions and Implications) 188 Game-changing Strategies 193 Appendix 195NBB6-52 4. Research TeamLead Analyst Contributing AnalystDeborah Toscano Jennifer BriceSenior Industry Analyst Global Program ManagerLife Sciences Life SciencesResearch Director Strategic Review Committee LeaderDaniel Ruppar Greg CaressiResearch Director Sr. Bad habit PresidentHealthcare HealthcareNBB6-52 5. Official Summary—CEO's Perspective Growth opportunity in the IBD business sector lies in 1 presentation of enhanced items, though the IBS business sector is generally undiscovered. Comfort, adequacy, security, and bearableness 2 are fundamental to the accomplishment of new treatments. More medication treatments must be created for 3 IBD patients who come up short first line treatments. Gastrointestinal inside scatters influence a 4 extensive populace over a wide demographic. Techniques to streamline tolerant adherence to 5 treatment could significantly enhance general clinical results and item achievement. Source: Frost & Sullivan analysis.NBB6-52 6. Market Overview—Segmentation Total Bowel Disorders Prescription Pharmaceuticals Market: Market Segmentation, U.S., 2011 Total Bowel Disorders Prescription Pharmaceuticals Market IBS IBD IBS-C IBS-D CD* UC* Oral or Injectable Treatments Topical Treatments***Considered by and large in forecasts** Not assessed in this exploration Source: Frost & Sullivan examination. NBB6-52 7. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Segmentation, U.S., 2011 Inflammatory Bowel Disease Prescription Pharmaceuticals Market CD UC Oral or Injectable Treatments Topical Treatments* 5-ASA Antibiotics* Corticosteroid Antimetabolite* Biologicals Novel Orals** ASA Corticosteroid TNFs Non-TNF Biologicals•Not secured in this examination service** Investigational; none yet sanction for IBD Source: Frost & Sullivan investigation. NBB6-52 8. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Market Segmentation, U.S., 2011 Irritable Bowel Syndrome Prescription Pharmaceuticals Market IBS-C IBS-M* IBS-D 5-HT3 (serotonin) Chloride channel (ClC-2) activator (diuretic) adversary Guanylate cyclase sort C receptor agonist*Not secured in this exploration benefit because of absence of sanction therapiesNote: Subsegmentation of the IBS business sector portion is not gave because of low level of business movement Source: Frost & Sullivan examination. NBB6-52 9. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011 IBS-C Drugs, 5.5% IBS-D Drugs, 1.1% Corticosteroids, 8.6 % TNF inhibitors, 48.7% Biologicals, 49.5% 5-ASA, 35.3% Non-TNF biologicals, 0.8% Note: All figures are adjusted. The base year is 2011. Source: Frost & Sullivan analysis.NBB6-52
Просмотров: 22 DailySlides
US Anthrax Drugs
 
01:40
Washington, DC Oct. 26, 2001 APTN 1. ws executives coming to microphone 2. cutaway press 3. SOUNDBITE: Chief Operating Officer of GlaxoSmithKline, Bob Ingram, "We have committed that we will work closely with the Food and Drug Administration to expedite the approval for the use of two of our antibiotics, Augmentin and Amoxil against the anthrax strain, and if those are approved we will then donate those free of charge to anyone infected or exposed to anthrax. Secondly, we've sent in our proposal yesterday to commit to supply smallpox vaccine within that one year period we've condensint I hope everyone understands from five to one eight years down to one as several other companies are committing to." 4. ws press 5. SOUNDBITE: Peter Goland, CEO Bristol-Meyers Squibb, "In my company's case, Briston Myers Squibb, we're offering to make our antibiotic available, Tequin, assuming it's approved for the anthrax indication, at no cost to anyone who contracts that illness. Secondly, we're offering 20 to 25 scientists who have experience in antibacterial in voroligy who can work as part of a bioterrorism team to address the country's threats and needs at this time." 6. cutaway press 7. ws executives walking away STORYLINE: Leaders of major pharmaceutical companies detailed steps the companies have taken since September 11 to assist the government's efforts to protect the public health, including providing the public with free anthrax drugs which are alternatives to Cipro. The Pharmaceutical Research and Manufacturers of America (PhRMA) said the companies are coordinating their efforts as part of a newly-created Task Force on Emergency Preparedness. Pharmaceutical companies outlined a wide-range of efforts they are working on to meet new threats at a meeting with Health and Human Services Secretary Tommy Thompson in Washington Friday. Initiatives include offers of free antibiotics to authorities to treat people infected by or exposed to anthrax; offers to develop and manufacture a smallpox vaccine; pledges to increase production of certain medicines as needed; giving government scientists access to company laboratories and production facilities; making company scientists available to work in government facilities as needed. The PhRMA represents the country's leading research-based pharmaceutical and biotechnology companies. The companies are offering an alternative to Cipro, the most popular anthrax drug on the market. The patent-holding maker of Cipro, Bayer Corp., has been ramping up retail production to 100 million tablets by mid-January, according to company officials. That is in addition to the 100 million pills the company agreed to supply to the U.S. government for emergency use at a cost of 95 cents apiece. The government is stockpiling Cipro for use where it is most needed in a national emergency. A jump of nearly 50 percent in prescriptions nationwide for Cipro shows that many doctors and patients are shrugging off government pleas against stockpiling for personal use, medical and industry experts say. In the New York City area, prescriptions nearly tripled, drug marketing data indicate. Spurred by news reports on potential bioterrorism, sales of the antibiotic began climbing right after the Sept. 11 air attacks and weeks before the first news of an anthrax case on Oct. 4, according to a national marketing consultant that surveys pharmaceutical retailers. The numbers are apt to rise more still as they are released in coming weeks, because the latest data go only as far as Oct. 12 - before the last anthrax deaths and widespread Cipro treatment for postal workers. Increases were especially heavy in Washington too, which together with New York suffered the brunt of the Sept. 11 attacks. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/a50f91724d04280e039ad4aea9dbc2cc Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 98 AP Archive
Marianne Williamson: On Consciousness, Spirituality, and Politics in America
 
02:17:49
Internationally acclaimed spiritual leader, Marianne Williamson, shares her insight on the creation of a beloved community through the use of political and ethical externalization. This lecture was delivered at Harvard Divinity School on October 14, 2015. Learn more about Harvard Divinity School and its mission to illuminate, engage, and serve at www.hds.harvard.edu.
Просмотров: 65707 Harvard Divinity School
Newsworthy Numbers - Part 1
 
01:02
British researchers found that study participants with Vitamin D levels below 50 nanomoles per liter, the minimum healthy level, were up to two times more likely to suffer from dementia than those with higher levels. $7.9 billion is the amount of money spent last year on Sovaldi, a treatment for hepatitis C and the prescription drug with the highest U.S. sales. Last year, spending on prescription drugs reached $374 billion. That’s up 13% from 2013 according to a study by the IMS Institute for Healthcare Informatics. 270 servings per person per year, that’s the volume of single-serve, unflavored bottled water in the U.S. marketplace.
Просмотров: 11 HometownHealth
April 17, 2015 Financial News - Business News - Stock Exchange - NYSE - Market News
 
03:47
April 17, 2015 Financial News - Business News - Stock Exchange - NYSE - Market News CLICK HERE➡ ➡ http://FinancialBuzz.com Business News - Financial News - Stock News -- New York Stock Exchange -- Market News 2015 Business News - Financial News - Stock Exchange -- Wall Street -- Market News - New York Stock Exchange 2015 On Monday, no economic numbers were released, so markets trended downward as everyone waited for the beginning of earnings season. On Tuesday, the producer price index for March rose .2% month to month, up from -.5%, and in line with expectations. Retail sales for March rose .9%, up from -.5%, and slightly below expectations. Markets were mixed, however, energy stocks rallied as crude oil rose nearly 3% to a little over $53 a barrel after forecasters predicted a decline in U.S. shale production. On Wednesday, industrial production for March declined .6%, compared to a .1% increase in February. In addition, the Empire State manufacturing survey for April showed a contraction reading of -1.19, only the second negative reading in the last 23 months. Crude oil continued rising, closing at over $56 a barrel, and this prompted a rally, with the Nasdaq closing above 5,000. On Thursday, housing starts for March were up 2%, disappointing analysts, and jobless claims for the week ending April 11th were up 12,000 to 294,000, higher than expected. On Friday, the consumer price index for March was up .2%, mostly due to higher energy costs. However, news of Greece having debt paying issues, and China's regulators implementing stricter margin regulations, cause a steep drop in markets. Now let’s take a look at some stocks. Mylan (NASDAQ: MYL) shares slumped while shares of Perrigo gained early this week following the news that Mylan, a pharmaceutical company specializing in generic drugs, made a $28.9 billion offer to acquire rival Perrigo. JPMorgan Chase & Co. (NYSE: JPM) shares spiked Tuesday to almost $63, following the release of their first quarter earnings showing a 12% increase in profit. JPMorgan’s net income increased to $5.91 billion on earnings of $1.45 per share, ahead of forecasts of $1.41 per share. The company reported increases in profits across all business units; investment banking up 12%, trading for fixed income, currencies and commodities up 5%, consumer banking up 12% and commercial banking up 1%. Nokia Corporation (NYSE: NOK) and Alcatel-Lucent Alcatel-Lucent (NYSE: ALU) stocks tumbled on Wednesday, after Nokia announced that they will be acquiring the French technology company in an all-stock deal that values Alcatel-Lucent at $16.6 billion. The combined company will have more than 114,000 employees and will be the second largest company in the mobile equipment industry. Citigroup Inc. (NYSE: C) shares made headlines on Thursday, gaining more than 1.5%, after releasing a first quarter earnings report showing the largest earnings the bank has seen in nearly eight years. Operating expenses decreased more than 10% while various business units’ revenue increased. Citigroup’s revenue for the first quarter came in at $19.7 billion or $1.51 per share while analysts forecasted earnings of only $1.39 per share. Netflix, Inc. (NASDAQ: NFLX) stock increased over 18% Thursday, and reached a new 52-week high, after the video streaming company released their first quarter financials, revealing major growth in their subscriber base. They had 4.9 million new subscribers, nearly a million more than what analysts expected. Netflix also reported an increase in revenue of 31%, year-over-year, to $1.4 billion. April 17, 2015 Weekly Stock Market Wrap-up: Mylan (NASDAQ: MYL) JPMorgan Chase & Co. (NYSE: JPM) Nokia Corporation (NYSE: NOK) Alcatel-Lucent (NYSE: ALU) Citigroup Inc. (NYSE: C) Netflix, Inc. (NASDAQ: NFLX) Business News - Financial News - Stock Exchange - New York Stock Exchange -- Wall Street -- Market News 2015 http://www.financialbuzz.com financial news, financial stock news, business news, stock news, financial news today, stock news today 2015, financial news now, stock news now, stock news, business news, financial news, © 2011 Financial Buzz. All rights reserved. No portion of FinancialBuzz.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law
Просмотров: 9378 FinancialBuzzMedia
Global Medical Devices Market 2012-2020: Market Size, Share, Trends, Analysis and Forecast
 
02:18
Market Research Reports, Inc. has announced the addition of “Global Medical Devices Market 2012-2020: Market Size, Share, Trends, Analysis and Forecast” research report to their offering. See more at- http://mrr.cm/4eV
Просмотров: 57 Market Research Reports, Inc.
AppExchange for Life Sciences: Where Cloud Meets Compliance
 
38:30
The Life Sciences industry has unique needs and requirements, from Global Regulatory Compliance to Clinical Trial Management, from Quality Manufacturing to Device Tracking, and more! Join us to learn why partners are choosing the Salesforce1 platform to develop apps for Life Sciences and how customers are succeeding using those apps. We'll share apps that have been built specifically to address the needs of medical devices and pharmaceutical organizations, as well as apps that make your users more productive. You'll walk away with real-world knowledge of how to further your investments in Salesforce technologies.
Просмотров: 517 Dreamforce Video
Country’s Largest Telecoms Are Giving The Government Your Personal Data - The Ring Of Fire
 
07:17
AT&T is one of the top companies helping the NSA collect the private data of U.S. citizens. Not once during the Republican debates has the issue of domestic spying been brought up, but the problem just seems to be getting worse Michael Burg will tell us how telecom giant AT&T is helping the NSA get their hands on your private data, and why the issue of domestic spying is being overshadowed in this election cycle. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 598 The Ring of Fire
Key & Peele - The Telemarketer - Uncensored
 
03:32
A telemarketer employs an aggressive new technique to sell vacation packages.
Просмотров: 11205058 Comedy Central
SKF India- Pune Factory
 
07:12
SKF's Pune factory is one among the more than 90 SKF production facilities around the world, that work tirelessly to meet the ever increasing global demand of high quality SKF bearings. While the people in the Pune factory come from a spectrum of diverse cultures and speak different languages, there is one overriding feature that unites them all: SKF Quality.
Просмотров: 229171 Lovina Raymond
Phone Sales Tips | Smile & Dial Sales App
 
01:13
Available Now! https://itunes.apple.com/us/app/smile-dial-pro-sales-tracker/id961982238?mt=8&uo=4&at=1l3vvY7 Are you looking for Phone Sales Tips? Then check out our Smile & Dial Sales App...... ================================================ Welcome to Smile & Dial!! We believe the most highly effective way to generate new clients, is simply picking up the phone and start dialing. Let’s be honest, making sales calls is not always easy to do, but with the Smile & Dial app we not only keep track of your dials, but will be there by your side to help inspire and motivate you along the way. FEATURES GOAL TRACKING By setting daily goals to focus on, Smile & Dial helps you easily and consistently hit your monthly and annual sales numbers. CALL ACTIONS As you move towards your goals, you’ll receive additional coaching and motivational tips to keep you moving forward. COACHING TIPS We’ll help you make each call more likely to succeed and convert into a paying customer or a satisfied client. CALL STATS Seeing the results of your daily progress as you work, encourages you even more to achieve your goals and go beyond them. MOTIVATIONAL QUOTES Refuel your passions for the sale and avoid burnout by consistently being reminded of a winning mindset. smileanddialapp.com
Просмотров: 709 Smile & Dial Sales App
Nightly Business Report: Hepatitis C drug pricing weighs on Gilead
 
02:09
Gilead said in its earnings report that it gave insurers steeper-than-expected discounts on its hepatitis C drugs.
Просмотров: 225 NBRbizrpt
Interview with a Business and Transformation Coach - Pharma Commercial Excellence MENA Congress
 
03:43
Samir Bata’s expertise in management, leadership, training and development has been built in 26 years in key positions in pharmaceuticals sales, marketing, national operations management and business development covering Middle East and Europe. He is a results-oriented leader who is acquainted to work with multinationals from diversified cultural backgrounds. Has a worldwide experience in training delivery and coaching many nationalities across Middle East, East Asia and Europe. He directly assessed and trained more than 25,000 people from all management and business leadership levels. During this interview, Samir Bata shares his insights about the importance of adopting an effective commercial and sales model in the pharmaceutical industry. Samir Bata is a speaker and workshop leader at the Pharma Commercial Excellence MENA Congress taking place from 16-19 February 2015 in Dubai. For more details about the congress, please visit www.mepharmaexcellence.com
Просмотров: 78 Negin Bagherian
Bal Pharma
 
02:01
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA Companies Data is publicly available. Data and calculations have been sourced from our Team, “Sharadar”, (http://www.sharadar.com), Rufus Pollock and from the Open Knowledge Foundation. All data is licensed under the Open Data Commons Public Domain Dedication and License. Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: company@whyinvestin.com
Просмотров: 265 Why Invest In
Surprising Blood Test Results (And You're Probably Deficient In It, Too) | VitaLivesFree
 
08:39
You can see the actual numbers here: http://vitalivesfree.com/surprising-blood-test-results/ Hi guys! Last week I was shocked to find out that I was deficient in something that I was sure I was getting plenty of. After researching non-stop, I now know that most of us are at risk and you should all go and have a blood test done, too. This one little sunshine vitamin is responsible for pretty much every single process in the body and anything, from depression to tooth decay to acne, can be caused or exacerbated by it. Please run to your doctor right now and request a blood test or do it privately (it really doesn't cost much). There are also ways you can do it by post. The test you need is called 25-Hydroxyvitamin D (or 25OHD). Don't delay, find out if you need it (I bet you do), and claim your vitality back! Also make sun your best friend. Moderate sun exposure without sunscreen and without burning is the best way to have adequate Vitamin D levels and boost your overall health. I'll be talking much more about Vitamin D in the future and I'll be updating you on my progress (I'll take a follow-up blood test in 3 months), so stay tuned! If you found this video interesting, please share it with your loved ones, so they will also go and get checked out. Have you been diagnosed with Vitamin D deficiency before? How did you raise it up? How are you maintaining it? I'd love to hear from you! Thanks for watching the video! Simply yours, Vita xx SUBSCRIBE for more videos → http://www.youtube.com/user/EcceVita1?sub_confirmation=1 Visit my BLOG → http://vitalivesfree.com WHERE ELSE YOU CAN FIND ME: ------------------------------------------------------ Blog → http://vitalivesfree.com Facebook → http://www.facebook.com/VitaLivesFree Google+ → https://plus.google.com/+Vitalivesfree Twitter → http://www.twitter.com/VitaLivesFree Pinterest → http://www.pinterest.com/VitaLivesFree Instagram → VitaLivesFree Email → vita(at)vitalivesfree.com
Просмотров: 1581 VitaLivesFree
SUPERMODELS SECRETS in a nutshell - Online e commerce beauty store malaysia
 
12:27
Founder of Supermodels Secrets Sdn. Bhd ( http://www.supermodel2u.com ). Online Entrepreneur / Part time Social Media Speaker INSTAGRAM @supermodels_secrets Michelle Chuah founded Supermodels Secrets - a beauty e-tailer in Malaysia since July 2010. With its humble beginnings as a one-man-show blogshop operating from home with only 2 products, she has spearheaded the organic growth of the company to over 600 products and a team of 7 employees with two brick-and-mortar stores over the years primarily via social media marketing and online media. Michelle has been actively involved in social media and digital marketing for more than five years and has a knack for Instagram marketing. She has worked with various companies in the fields of IT, Pharmaceutical sector as well as large commercial companies such as FedEx upon her graduation from the Chartered Institute of Marketing, UK. In year 2008 she left the corporate world due to health reasons - her right eye got blinded from a parasite scar - and got involved in the modelling industry as it was less taxing to her health - her modelling stint soon inspired the birth of Supermodels Secrets offering products for women to look beautiful instantly. Her mission for Supermodels Secrets is to help women look beautiful from head to toe in the shortest time possible in light of today's growing number of busy corporate women. With the volatile online marketing/social media landscape challenging marketeers the world over, Michelle has managed to overcome them with marketing hacks that allows e commerce businesses to flourish in the ever changing marketing environment and can tackle them hands-on, garnering her an invaluable social media marketing experience to grow a successful online business. ◑ My Blog: www.supermodels-secrets.com ◒ My Facebook: http://facebook.com/ilovesupermodel2u ◓ My Instagram: http://instagram.com/supermodels_secrets ◒ My Website: SUPERMODELS SECRETS BEAUTY STORE http://www.supermodelmy.com (Malaysia & Asia online store) http://www.supermodel2u.com (USA, Europe, Australia & other countries)
Просмотров: 1393 Supermodels Secrets
K Camp - Comfortable
 
03:56
K Camp’s debut album “Only Way Is Up” Available NOW iTunes Deluxe Explicit: http://smarturl.it/KCampOWIUdlxEX Google Play Standard Explicit: http://smarturl.it/KCampOWIUstdEXgp Google Play Standard Clean : http://smarturl.it/KCampOWIUstdEDgp Google Play Explicit Deluxe: http://smarturl.it/KCampOWIUdlxEXgp Google Play Clean Deluxe: http://smarturl.it/KCampOWIUdlxEDgp http://kcamp427.com http://twitter.com/twitter.com/kcamp427 http://facebook.com/kcamp427 http://instagram.com/kcamp427 http://vevo.ly/h1MhCH
Просмотров: 59489551 KCampVEVO
Congressional Probe Finds Drugmaker Put Profits First
 
01:46
The makers of a costly hepatitis drug put profits ahead of patient affordability and accessibility when pricing the medication, according to the findings of a congressional investigation unveiled Tuesday. The 18-month probe, led by Senate Finance Committee ranking Democrat Ron Wyden of Oregon and Republican Charles E. Grassley of Iowa, reviewed 20,000 pages of documents and conducted dozens of interviews to determine how Gilead Sciences priced Sovaldi and a successor medicine, Harvoni. Wyden and Grassley said at a press conference Tuesday that Gilead remained focused on maximizing profits even though the company was aware that a lower medication price would have allowed more patients to be treated. Website: http://www.rollcall.com Follow us: http://www.twitter.com/RollCall Like us: http://www.facebook.com/RollCallDC Google+: http://www.google.com/+RollCall Tumblr: http://photos.rollcall.com
Просмотров: 456 Roll Call
Wall Street Looks Ahead for Earnings From Credit Suisse, CBS & Key Economic Data
 
01:04
For Thursday, February 12th, Wall Street will be watching for more earnings and key economic data. Investment bank Credit Suisse (CS), Kellogg Company (K) and Avon Products (AVP) will report financial results before the opening bell. At the close, CBS Corporation (CBS) and Columbia Sportswear Company (COLM) report results, along with American International Group (AIG). Analysts expect earnings per share of $1.05 on revenue of $9.4 billion for the insurance giant. Plus, the monthly retail sales numbers for January will be released at 8:30am eastern by the Census Bureau. Analysts expect a 0.5% drop in sales during the month. This is a key economic indicator that helps gauge consumer spending, which accounts for two-thirds of gross domestic product. Also at 8:30, the weekly jobless claims numbers are released, followed by business inventories at 10am and the EIA Natural Gas Report at 10:30. TheStreet's Scott Gamm reports from New York. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 54 TheStreet: Investing Strategies